Last reviewed · How we verify
Anti-Adhesion Product
At a glance
| Generic name | Anti-Adhesion Product |
|---|---|
| Sponsor | Baxter Healthcare Corporation |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) (PHASE1, PHASE2)
- Prospective Comparison of the Effect on Antiadhesive Barriers During Thyroid Surgery (PHASE1)
- A Study of SIGX1094R in Patients With Advanced Solid Tumors (PHASE1)
- Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL) (PHASE2)
- Clinical Study of the Effectiveness, Tolerability and Safety of the Drug "Anti-spike, Gel, 100 g in Bottles in Package No. 1" Produced by the Republican Unitary Enterprise "Unitekhprom BSU", With a Single Intraperitoneal Use After Surgery in Adult Patients With Acute Phlegmonous Appendicitis (PHASE2)
- CARIES ARREST USING SILVER DIAMINE FLUORIDE VERSUS FISSURE SEALANT in OCCLUSAL DENTAL CARIOUS LESIONS: RANDOMIZED CONTROLLED TRIAL (NA)
- Hysteroscopy vs. Endouterine Aspiration in the Management of Trophoblastic Retention (NA)
- A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-Adhesion Product CI brief — competitive landscape report
- Anti-Adhesion Product updates RSS · CI watch RSS
- Baxter Healthcare Corporation portfolio CI